Description
Requip XL Uzatılmış Salımlı Tablet 4 mg is a pharmaceutical preparation containing the active ingredient ropinirole hydrochloride at a dose of 4 mg. It is an extended-release formulation primarily used in the management of neurological movement disorders. This medication is commonly prescribed in Turkey and other countries for conditions such as Parkinson’s disease and restless legs syndrome (RLS).
What is Requip XL?
Requip XL is an extended-release tablet form of ropinirole, a dopamine agonist that mimics the action of dopamine, a neurotransmitter essential for controlling movement in the brain. The extended-release formulation allows for once-daily dosing, providing a steady release of the medication over time to maintain consistent therapeutic effects.
Indications and Uses
Parkinson’s Disease
Requip XL is indicated for the treatment of symptoms associated with Parkinson’s disease, a progressive neurological disorder characterized by tremors, muscle stiffness, slowed movements (bradykinesia), and impaired balance. Ropinirole helps alleviate these symptoms by stimulating dopamine receptors in the brain, compensating for the dopamine deficiency seen in Parkinson’s disease.
Restless Legs Syndrome (RLS)
Although the immediate-release form of ropinirole is more commonly used for RLS, ropinirole in general is effective in reducing the uncomfortable sensations and urge to move the legs that characterize this condition, particularly in moderate to severe cases.
Mechanism of Action
Ropinirole acts as a non-ergoline dopamine agonist, binding to dopamine receptors in the central nervous system, primarily D2-type receptors. By activating these receptors, it substitutes for the diminished dopamine levels in patients with Parkinson’s disease or RLS, thereby improving motor control and reducing symptoms such as tremors and leg discomfort.
Dosage and Administration
-
The usual starting dose of Requip XL is 2 mg once daily.
-
The dose may be gradually increased by 2 mg increments at weekly intervals based on patient response and tolerability.
-
Typical maintenance doses range from 4 mg to 8 mg daily, but doses up to 24 mg per day may be used under medical supervision.
-
The tablet should be swallowed whole and not chewed or crushed to maintain the extended-release properties.
Storage
Requip XL should be stored at room temperature, ideally between 20°C to 25°C (68°F to 77°F), protected from moisture and light. Short-term exposure to temperatures between 15°C to 30°C (59°F to 86°F) is acceptable during transport.
Side Effects
Common side effects associated with Requip XL (ropinirole) include:
| Side Effect | Description |
|---|---|
| Nausea and vomiting | Gastrointestinal discomfort |
| Dizziness | May cause lightheadedness or fainting |
| Fatigue and drowsiness | Excessive sleepiness or sudden sleep episodes |
| Headache | Mild to moderate headaches |
| Orthostatic hypotension | Drop in blood pressure upon standing |
| Hallucinations | Visual or auditory hallucinations, especially in elderly patients |
| Dyskinesia | Involuntary movements |
| Confusion | Cognitive disturbances |
Serious adverse effects such as sudden sleep attacks, psychosis, or severe hypotension require immediate medical attention.
Benefits
-
Provides symptomatic relief in Parkinson’s disease by improving motor function.
-
Helps delay the need for levodopa therapy in early Parkinson’s disease.
-
Improves quality of life by reducing symptoms of restless legs syndrome.
-
Extended-release formulation allows for once-daily dosing, enhancing compliance.
Usage Precautions
-
Patients should inform their healthcare provider about any history of heart disease, psychiatric disorders, or kidney/liver problems.
-
Caution is advised when driving or operating machinery due to potential drowsiness or sudden sleep episodes.
-
Dosage adjustments may be necessary in elderly patients or those with hepatic impairment.
-
Abrupt discontinuation should be avoided to prevent withdrawal symptoms.
Requip XL Uzatılmış Salımlı Tablet 4 mg
| Category | Information |
|---|---|
| Active Ingredient | Ropinirole hydrochloride 4 mg (extended-release) |
| Drug Class | Dopaminergic antiparkinsonism agent (dopamine agonist) |
| Indications | Parkinson’s disease, Restless Legs Syndrome (off-label or immediate-release preferred for RLS) |
| Mechanism | Stimulates dopamine receptors to compensate for dopamine deficiency |
| Dosage | Start 2 mg once daily; increase by 2 mg weekly; maintenance 4–8 mg/day; max 24 mg/day |
| Administration | Oral, swallow whole; do not chew or crush |
| Common Side Effects | Nausea, dizziness, drowsiness, headache, orthostatic hypotension, hallucinations |
| Serious Side Effects | Sudden sleep episodes, psychosis, severe hypotension |
| Storage | Room temperature (20–25°C), protect from moisture and light |
| Precautions | Use caution with driving; inform doctor of medical history; do not abruptly stop medication |
Conclusion
In conclusion, Requip XL Uzatılmış Salımlı Tablet 4 mg is a clinically effective extended-release ropinirole formulation used to manage Parkinson’s disease symptoms and, in some cases, restless legs syndrome. Its dopamine agonist activity helps restore motor function and improve patient quality of life. Proper dosing, monitoring for side effects, and adherence to administration guidelines are essential for safe and effective treatment.
Reviews
There are no reviews yet.